Laquinimod capsules 0.5 mg    (DrugBank: Laquinimod)

2 diseases
IDDisease name (Link within this page)Number of trials
8Huntington disease5
96Crohn disease3

8. Huntington disease    [ 197 clinical trials,   171 drugs,   (DrugBank: 54 drugs),   82 drug target genes,   144 drug target pathways]
Searched query = "Huntington disease", "Huntington chorea"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
5 / 197 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2014-000418-75-NL
(EUCTR)
04/11/201515/10/2014A clinical study in subjects with Huntington's Disease to assess the efficacy and safety of three oral doses of laquinimod, either 0.5 mg/day, 1.0 mg/day or 1.5 mg/day (experimental drug)A Multicenter, Multinational, Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Laquinimod (0.5, 1.0 and 1.5 mg/day) as Treatment in Patients with Huntington's Disease - LEGATO-HD (Laquinimod Efficacy and Safety in a GlobAl Trial Of HD) Huntington's Disease (HD)
MedDRA version: 18.1;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: Laquinimod capsules 0.5 mg
Product Code: TV-5600
INN or Proposed INN: LAQUINIMOD
Other descriptive name: 5-Chloro-1,2-dihydro-N-ethyl-4-hydroxy-1-methyl-2-oxo-N-phenyl-3-quinolinecarboxamide sodium
Teva Branded Pharmaceutical Products R&D, Inc.NULLNot RecruitingFemale: yes
Male: yes
330Phase 2Portugal;United States;Czech Republic;Canada;Spain;Russian Federation;Germany;Netherlands;Italy;United Kingdom
2EUCTR2014-000418-75-DE
(EUCTR)
06/01/201525/09/2014A clinical study in subjects with Huntington's Disease to assess the efficacy and safety of three oral doses of laquinimod, either 0.5 mg/day, 1.0 mg/day or 1.5 mg/day (experimental drug)A Multicenter, Multinational, Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Laquinimod (0.5, 1.0 and 1.5 mg/day) as Treatment in Patients with Huntington's Disease - LEGATO-HD (Laquinimod Efficacy and Safety in a GlobAl Trial Of HD) Huntington's Disease (HD)
MedDRA version: 20.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: Laquinimod capsules 0.5 mg
Product Code: TV-5600
INN or Proposed INN: LAQUINIMOD
Other descriptive name: 5-Chloro-1,2-dihydro-N-ethyl-4-hydroxy-1-methyl-2-oxo-N-phenyl-3-quinolinecarboxamide sodium
Teva Branded Pharmaceutical Products R&D, Inc.NULLNot RecruitingFemale: yes
Male: yes
330Phase 2Portugal;United States;Czech Republic;Canada;Spain;Russian Federation;Netherlands;Germany;Italy;United Kingdom
3EUCTR2014-000418-75-CZ
(EUCTR)
05/01/201525/09/2014A clinical study in subjects with Huntington's Disease to assess the efficacy and safety of three oral doses of laquinimod, either 0.5 mg/day, 1.0 mg/day or 1.5 mg/day (experimental drug)A Multicenter, Multinational, Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Laquinimod (0.5, 1.0 and 1.5 mg/day) as Treatment in Patients with Huntington's Disease - LEGATO-HD (Laquinimod Efficacy and Safety in a GlobAl Trial Of HD) Huntington's Disease (HD)
MedDRA version: 19.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: Laquinimod capsules 0.5 mg
Product Code: TV-5600
INN or Proposed INN: LAQUINIMOD
Other descriptive name: 5-Chloro-1,2-dihydro-N-ethyl-4-hydroxy-1-methyl-2-oxo-N-phenyl-3-quinolinecarboxamide sodium
Teva Branded Pharmaceutical Products R&D, Inc.NULLNot RecruitingFemale: yes
Male: yes
330Phase 2Portugal;United States;Czech Republic;Canada;Spain;Russian Federation;Netherlands;Germany;Italy;United Kingdom
4EUCTR2014-000418-75-IT
(EUCTR)
18/11/201425/08/2014A clinical study in subjects with Huntington's Disease to assess the efficacy and safety of three oral doses of laquinimod, either 0.5 mg/day, 1.0 mg/day or 1.5 mg/day (experimental drug)A Multicenter, Multinational, Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Laquinimod (0.5, 1.0 and 1.5 mg/day) as Treatment in Patients with Huntington's Disease - LEGATO-HD (Laquinimod Efficacy and Safety in a GlobAl Trial Of HD) Huntington's Disease (HD)
MedDRA version: 17.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: Laquinimod capsules 0.5 mg
Product Code: TV-5600
INN or Proposed INN: LAQUINIMOD
Other descriptive name: 5-Chloro-1,2-dihydro-N-ethyl-4-hydroxy-1-methyl-2-oxo-N-phenyl-3-quinolinecarboxamide sodium
Teva Branded Pharmaceutical Products R&D, Inc.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
400Portugal;France;United States;Czech Republic;Canada;Spain;Netherlands;Germany;United Kingdom;Italy
5EUCTR2014-000418-75-ES
(EUCTR)
23/10/201416/10/2014A clinical study in subjects with Huntington's Disease to assess the efficacy and safety of three oral doses of laquinimod, either 0.5 mg/day, 1.0 mg/day or 1.5 mg/day (experimental drug)A Multicenter, Multinational, Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Laquinimod (0.5, 1.0 and 1.5 mg/day) as Treatment in Patients with Huntington's Disease - LEGATO-HD (Laquinimod Efficacy and Safety in a GlobAl Trial Of HD) Huntington's Disease (HD)
MedDRA version: 17.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: Laquinimod capsules 0.5 mg
Product Code: TV-5600
INN or Proposed INN: LAQUINIMOD
Other descriptive name: 5-Chloro-1,2-dihydro-N-ethyl-4-hydroxy-1-methyl-2-oxo-N-phenyl-3-quinolinecarboxamide sodium
Teva Branded Pharmaceutical Products R&D, Inc.NULLNot RecruitingFemale: yes
Male: yes
400Phase 2Portugal;France;United States;Czech Republic;Canada;Spain;Netherlands;Germany;Italy;United Kingdom

96. Crohn disease    [ 2,209 clinical trials,   1,276 drugs,   (DrugBank: 240 drugs),   166 drug target genes,   210 drug target pathways]
Searched query = "Crohn disease", "Terminal ileitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
3 / 2,209 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2008-004276-49-FR
(EUCTR)
18/12/200821/07/2008A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Sequential Cohorts, Dose Range Finding Study to Evaluate the Safety, Tolerability and Clinical Effect of Escalating Doses of Laquinimod in Active Moderate to Severe Crohn’s DiseaseA Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Sequential Cohorts, Dose Range Finding Study to Evaluate the Safety, Tolerability and Clinical Effect of Escalating Doses of Laquinimod in Active Moderate to Severe Crohn’s Disease Moderate to severe Crohn's disease (CD)
MedDRA version: 9.1;Level: PT;Classification code 10011401;Term: Crohn's disease
Product Name: Laquinimod Capsules 0.5 mg
Product Code: TV-5600
INN or Proposed INN: laquinimod
Other descriptive name: ABR-215062 sodium salt
Teva Pharmaceutical Industries Ltd.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
199Phase 2aUnited Kingdom;Netherlands;Belgium;France;Spain;Italy
2EUCTR2008-004276-49-NL
(EUCTR)
14/10/200805/08/2008A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Sequential Cohorts, Dose Range Finding Study to Evaluate the Safety, Tolerability and Clinical Effect of Escalating Doses of Laquinimod in Active Moderate to Severe Crohn’s DiseaseA Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Sequential Cohorts, Dose Range Finding Study to Evaluate the Safety, Tolerability and Clinical Effect of Escalating Doses of Laquinimod in Active Moderate to Severe Crohn’s Disease Moderate to severe Crohn's disease (CD)
MedDRA version: 9.1;Level: PT;Classification code 10011401;Term: Crohn's disease
Product Name: Laquinimod Capsules 0.5 mg
Product Code: TV-5600
INN or Proposed INN: laquinimod
Other descriptive name: ABR-215062 sodium salt
Teva Pharmaceutical Industries Ltd.NULLNot RecruitingFemale: yes
Male: yes
199Phase 2aUnited Kingdom;Netherlands;Belgium;France;Spain;Italy
3EUCTR2008-004276-49-BE
(EUCTR)
07/10/200815/09/2008A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Sequential Cohorts, Dose Range Finding Study to Evaluate the Safety, Tolerability and Clinical Effect of Escalating Doses of Laquinimod in Active Moderate to Severe Crohn’s DiseaseA Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Sequential Cohorts, Dose Range Finding Study to Evaluate the Safety, Tolerability and Clinical Effect of Escalating Doses of Laquinimod in Active Moderate to Severe Crohn’s Disease Moderate to severe Crohn's disease (CD)
MedDRA version: 9.1;Level: PT;Classification code 10011401;Term: Crohn's disease
Product Name: Laquinimod Capsules 0.5 mg
Product Code: TV-5600
INN or Proposed INN: laquinimod
Other descriptive name: ABR-215062 sodium salt
Teva Pharmaceutical Industries Ltd.NULLNot RecruitingFemale: yes
Male: yes
180Phase 2France;Spain;Belgium;Netherlands;United Kingdom;Italy